, Sven-Oliver Trö bs 4, 3 and Philipp S Wild 1, 2, 3 Air pollution constitutes the most important environmental risk factor for cardiovascular disease (CVD) worldwide. 1 Both short and long-term exposure to fine particulate matter (PM) have been demonstrated to increase the risk of acute cardiovascular events predominantly attributed to the development of cardiometabolic conditions such as arterial hypertension, diabetes mellitus and obesity. [2] [3] [4] Pathophysiologically these states are currently perceived to be mediated by oxidative stress, impaired vascular function, low-grade systemic inflammation and a pre-thrombotic phenotype. [5] [6] [7] As obese individuals experience an elevated risk for the development of CVD as a result of several predisposing conditions such as chronic inflammation and oxidative stress, 8 they may be particularly susceptible to the effects of environmental pollutants.
In the current issue of the European Journal of Preventive Cardiology, Macchi and colleagues 9 investigated the interrelation of exposure to air pollution and the concentration of circulating levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) in obese subjects. Nested within the database of the Susceptibility to Particle Health Effects, miRNAs and Exosomes (SPHERE) study, they performed a crosssectional analysis, which demonstrated a positive association between long-term exposure to PM 10 and levels of PCSK9 in univariate analysis. Further adjustment for potential confounders revealed that this association was limited to obese individuals with lower levels of interferon-g. For short-term exposure to PM 10 , no significant associations were found. 9 PCSK9 binds to the receptor for low-density lipoprotein (LDL) particles and thereby initiates the internalisation of both LDL particles and the LDL receptor into the liver cells. Therapeutically, the blockade of PCSK9 with specific antibodies is paving new avenues in the management of dyslipidemia. 10 In contrast to the sound body of evidence demonstrating the effectiveness of this therapy, evidence with regard to the risk of CVD associated with elevated levels of PCSK9 is controversially discussed due to inconsistency between studies. [11] [12] [13] Nevertheless, the results demonstrated by Macchi et al. are in line with our current understanding of air pollution as a risk factor for the progression towards a cardiometabolic phenotype. Although this observation is not unexpected, it is the first investigation of its kind and provides novel insights adding to the complexity of the pathophysiology of air pollutioninduced detrimental effects in humans. Specific attention should also be raised to the notion that the association between PM 10 and levels of PCSK9 is dependent on the concentration of systemic interferon-g: this indicates that PCSK9-mediated effects of air pollution on the cardiovascular system may have additive value only in the absence of increased systemic inflammation. Against this background it merits specific consideration that only obese individuals were investigated in the study by Macchi et al. 9 Although obese individuals may be more susceptible to the detrimental effects of air pollution in general, these findings should be followed up by adequately powered prospective, populationbased studies. This will allow us to judge the representativeness and external validity of results as well as the clinical impact. As obese individuals constitute one specific population with an elevated risk of incident CVD, results may also differ among high-risk subgroups (e.g. subjects with type 2 diabetes or individuals with fatty liver disease). Moreover, it is important to note that Macchi and colleagues investigated PM 10 as a measure of air pollution only. 9 This partly limits the conclusion of study results regarding the exposure of lower degrees of PM (e.g. PM 2.5 ) and the different compositions of constituents (e.g. gaseous or solid), which have recently been shown to trigger the vascular damage conveyed by air pollution differently.
14 As carefully acknowledged by the authors the present report does not answer the question as to whether PCSK9 serves as an intermediate for the effects of PM exposure on cardiovascular risk. This raises the need for future studies, including the evaluation of the prognostic relevance of the interaction between air pollution and PCSK9 levels for the incidence of CVD including the comparison of nonthrombotic and thrombotic CVD outcomes.
To date, there is little evidence that serum PCSK9 is capable of capturing CVD risk beyond established risk factors, although studies have revealed biological roles of PCSK9 beyond regulating LDL cholesterol. This indicates that PCSK9 might -at least in partmirror metabolic and cardiovascular effects of air pollution. While we do not believe that PCSK9 concentrations will be suitable to improve cardiovascular risk assessment in the context of exposure to air pollution, a need for future clinical and mechanistic studies exploring the mechanisms behind the effects of air pollution on circulating PCSK9 (e.g. innate immune response, 15 inter-individual variation in PCSK9 levels) is clearly given. 16, 17 The data presented by Macchi and colleagues also remind us that cardiometabolic disease remains a central component in the complex pathophysiology of air pollution-induced CVD and reinforce the necessity for united public health efforts.
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